OrbiMed Advisors LLC
- SEC CIK
- 0001055951
- Latest filing
- Aug 14, 2026
Holdings in Q4 2023
Holdings as of Dec 31, 2023, filed Feb 14, 2024. Long positions only; changes compare share counts with Q3 2023.
- Positions
- 109
- −11 vs. Q3 2023
- Portfolio value
- $4.99B
- +$671.3M (+15.5%) vs. Q3 2023
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| SVASinovac Biotech Ltd | SHS | 2,718,735 | $340.0M | 6.8% | 00.0% | Unchanged | History |
| BIIBBiogen Inc. | COM | 827,600 | $214.2M | 4.3% | +270,800+48.6% | Added | History |
| LLYEli Lilly & Co | Stock | 365,400 | $213.0M | 4.3% | +179,400+96.5% | Added | History |
| BSXBoston Scientific Corp | Stock | 3,306,800 | $191.2M | 3.8% | 00.0% | Unchanged | History |
| ISRGIntuitive Surgical Inc | COM NEW | 499,000 | $168.3M | 3.4% | 00.0% | Unchanged | History |
| EWTXEdgewise Therapeutics, Inc. | COM | 14,567,176 | $159.4M | 3.2% | 00.0% | Unchanged | History |
| BMRNBiomarin Pharmaceutical Inc | COM | 1,571,410 | $151.5M | 3.0% | −43,800−2.7% | Reduced | History |
| RYZBRayzeBio, Inc. | COM | 2,365,213 | $147.0M | 2.9% | −257,696−9.8% | Reduced | History |
| ELVNEnliven Therapeutics, Inc. | COM | 8,998,338 | $124.5M | 2.5% | 00.0% | Unchanged | History |
| SWTXSpringWorks Therapeutics, Inc. | COM | 3,219,359 | $117.5M | 2.4% | −749,229−18.9% | Reduced | History |
| MRKMerck & Co., Inc. | Stock | 1,055,000 | $115.0M | 2.3% | 00.0% | Unchanged | History |
| IONSIonis Pharmaceuticals Inc | COM | 2,064,797 | $104.5M | 2.1% | −104,703−4.8% | Reduced | History |
| IRONDisc Medicine, Inc. | COM | 1,702,237 | $98.3M | 2.0% | −567,400−25.0% | Reduced | History |
| Gracell Biotechnologies Inc38406L103 | SPONSORED ADS | 9,308,726 | $93.5M | 1.9% | 00.0% | Unchanged | – |
| THCTenet Healthcare Corp | COM NEW | 1,224,400 | $92.5M | 1.9% | 00.0% | Unchanged | History |
| EVHEvolent Health, Inc. | CL A | 2,746,532 | $90.7M | 1.8% | −149,100−5.1% | Reduced | History |
| UTHRUnited Therapeutics Corp | COM | 386,100 | $84.9M | 1.7% | −15,800−3.9% | Reduced | History |
| XTNTXtant Medical Holdings, Inc. | COM NEW | 73,114,592 | $82.6M | 1.7% | 00.0% | Unchanged | History |
| SYKStryker Corp | Stock | 269,000 | $80.6M | 1.6% | 00.0% | Unchanged | History |
| SRRKScholar Rock Holding Corp | COM | 4,245,000 | $79.8M | 1.6% | +2,211,211+108.7% | Added | History |
| TMOThermo Fisher Scientific Inc. | Stock | 143,800 | $76.3M | 1.5% | 00.0% | Unchanged | History |
| VRNAVerona Pharma plc | SPONSORED ADS | 3,777,778 | $75.1M | 1.5% | 00.0% | Unchanged | History |
| PCVXVaxcyte, Inc. | COM | 1,153,091 | $72.4M | 1.5% | +145,943+14.5% | Added | History |
| THRXTheseus Pharmaceuticals, Inc. | COM | 17,713,600 | $71.7M | 1.4% | 00.0% | Unchanged | History |
| VRTXVertex Pharmaceuticals Inc | Stock | 175,200 | $71.3M | 1.4% | +9,800+5.9% | Added | History |
| NBIXNeurocrine Biosciences Inc | Stock | 519,279 | $68.4M | 1.4% | +103,379+24.9% | Added | History |
| SRPTSarepta Therapeutics, Inc. | COM | 697,500 | $67.3M | 1.3% | +168,300+31.8% | Added | History |
| ELVElevance Health, Inc. | Stock | 141,500 | $66.7M | 1.3% | +141,500 | New | History |
| THRDThird Harmonic Bio, Inc. | COM | 5,779,071 | $63.4M | 1.3% | 00.0% | Unchanged | History |
| NTRANatera, Inc. | COM | 954,481 | $59.8M | 1.2% | +33,900+3.7% | Added | History |
| CRNXCrinetics Pharmaceuticals, Inc. | COM | 1,667,360 | $59.3M | 1.2% | −1,228,714−42.4% | Reduced | History |
| APLSApellis Pharmaceuticals, Inc. | COM | 922,200 | $55.2M | 1.1% | −338,300−26.8% | Reduced | History |
| RCMR1 RCM Inc. | COM | 4,803,200 | $50.8M | 1.0% | +1,362,200+39.6% | Added | History |
| SPRYARS Pharmaceuticals, Inc. | COM | 9,240,887 | $50.6M | 1.0% | 00.0% | Unchanged | History |
| KROSKeros Therapeutics, Inc. | COM | 1,268,734 | $50.4M | 1.0% | −246,000−16.2% | Reduced | History |
| HUMHumana Inc | Stock | 109,900 | $50.3M | 1.0% | −232,600−67.9% | Reduced | History |
| TERNTerns Pharmaceuticals, Inc. | COM | 7,619,135 | $49.4M | 1.0% | 00.0% | Unchanged | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 2,535,245 | $48.3M | 1.0% | −1,546,347−37.9% | Reduced | History |
| SIBNSI-BONE, Inc. | COM | 2,292,531 | $48.1M | 1.0% | 00.0% | Unchanged | History |
| PRLDPrelude Therapeutics Inc | COM | 10,909,256 | $46.6M | 0.9% | 00.0% | Unchanged | History |
| ALXOAlx Oncology Holdings Inc | COM | 3,095,000 | $46.1M | 0.9% | +224,000+7.8% | Added | History |
| NPCENeuroPace Inc | COM | 4,003,967 | $41.3M | 0.8% | −8,314−0.2% | Reduced | History |
| IOVAIovance Biotherapeutics, Inc. | COM | 4,707,458 | $38.3M | 0.8% | 00.0% | Unchanged | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 1,749,000 | $37.8M | 0.8% | +465,000+36.2% | Added | History |
| ICLRIcon PLC | COM | 132,200 | $37.4M | 0.7% | 00.0% | Unchanged | History |
| UNHUnitedHealth Group Inc | Stock | 70,000 | $36.9M | 0.7% | 00.0% | Unchanged | History |
| 0000000000 | Stock | 12,048,773 | $36.8M | 0.7% | 00.0% | Unchanged | – |
| AMGNAmgen Inc | Stock | 127,300 | $36.7M | 0.7% | 00.0% | Unchanged | History |
| APGEApogee Therapeutics, Inc. | COM | 1,277,901 | $35.7M | 0.7% | −150,000−10.5% | Reduced | History |
| JANXJanux Therapeutics, Inc. | COM | 3,317,927 | $35.6M | 0.7% | 00.0% | Unchanged | History |
| CMPXCompass Therapeutics, Inc. | COM | 22,362,850 | $34.9M | 0.7% | 00.0% | Unchanged | History |
| SCPHscPharmaceuticals Inc. | COM | 5,559,528 | $34.9M | 0.7% | 00.0% | Unchanged | History |
| ARGXArgenx SE | SPONSORED ADR | 84,600 | $32.2M | 0.6% | +52,000+159.5% | Added | History |
| FUSNFusion Pharmaceuticals Inc. | COM | 3,122,770 | $30.0M | 0.6% | 00.0% | Unchanged | History |
| SLRNACELYRIN, Inc. | COM | 4,001,711 | $29.9M | 0.6% | −1,324,591−24.9% | Reduced | History |
| NMRANeumora Therapeutics, Inc. | COM | 1,500,000 | $25.6M | 0.5% | 00.0% | Unchanged | History |
| XENEXenon Pharmaceuticals Inc. | COM | 550,000 | $25.3M | 0.5% | −408,793−42.6% | Reduced | History |
| RYTMRhythm Pharmaceuticals, Inc. | COM | 536,642 | $24.7M | 0.5% | −47,000−8.1% | Reduced | History |
| RPTXRepare Therapeutics Inc. | COM | 3,322,488 | $24.3M | 0.5% | 00.0% | Unchanged | History |
| ABCLAbCellera Biologics Inc. | COM | 4,180,768 | $23.9M | 0.5% | 00.0% | Unchanged | History |
| VERAVera Therapeutics, Inc. | CL A | 1,518,115 | $23.3M | 0.5% | 00.0% | Unchanged | History |
| PMVPPMV Pharmaceuticals, Inc. | COM | 6,475,291 | $20.1M | 0.4% | −87,786−1.3% | Reduced | History |
| KNTEKinnate Biopharma Inc. | COM | 8,009,729 | $19.0M | 0.4% | 00.0% | Unchanged | History |
| TELATELA Bio, Inc. | COM | 2,835,542 | $18.8M | 0.4% | 00.0% | Unchanged | History |
| JBIOJade Biosciences, Inc. | COM | 756,930 | $17.1M | 0.3% | 00.0% | Unchanged | History |
| IVVDInvivyd, Inc. | COM | 4,127,565 | $16.3M | 0.3% | −1,142,835−21.7% | Reduced | History |
| IMTXImmatics N.V. | SHS | 1,543,407 | $16.3M | 0.3% | +493,207+47.0% | Added | History |
| ACETAdicet Bio, Inc. | COM | 8,322,140 | $15.7M | 0.3% | 00.0% | Unchanged | History |
| ALNYAlnylam Pharmaceuticals, Inc. | COM | 79,400 | $15.2M | 0.3% | +79,400 | New | History |
| KRYSKrystal Biotech, Inc. | COM | 103,700 | $12.9M | 0.3% | +103,700 | New | History |
| VSTMVerastem, Inc. | COM NEW | 1,529,115 | $12.4M | 0.2% | 00.0% | Unchanged | History |
| CRVSCorvus Pharmaceuticals, Inc. | COM | 6,943,654 | $12.2M | 0.2% | 00.0% | Unchanged | History |
| REGNRegeneron Pharmaceuticals, Inc. | COM | 13,500 | $11.9M | 0.2% | 00.0% | Unchanged | History |
| FOLDAmicus Therapeutics, Inc. | COM | 806,000 | $11.4M | 0.2% | +806,000 | New | History |
| PASGPassage BIO, Inc. | COM | 10,124,576 | $10.2M | 0.2% | 00.0% | Unchanged | History |
| HRTXHeron Therapeutics, Inc. | COM | 5,928,591 | $10.1M | 0.2% | +5,125,891+638.6% | Added | History |
| ARWRArrowhead Pharmaceuticals, Inc. | COM | 319,651 | $9.78M | 0.2% | −114,000−26.3% | Reduced | History |
| QUREuniQure N.V. | SHS | 1,347,900 | $9.13M | 0.2% | −716,555−34.7% | Reduced | History |
| DXCMDexcom Inc | COM | 73,200 | $9.08M | 0.2% | +73,200 | New | History |
| APLMApollomics Inc. | CL A SHS | 8,565,456 | $8.27M | 0.2% | −9,428,179−52.4% | Reduced | History |
| GILDGilead Sciences, Inc. | Stock | 100,000 | $8.10M | 0.2% | 00.0% | Unchanged | History |
| MORFMorphic Holding, Inc. | COM | 273,400 | $7.90M | 0.2% | +64,900+31.1% | Added | History |
| TSBXTurnstone Biologics Corp. | COM | 3,099,265 | $7.89M | 0.2% | 00.0% | Unchanged | History |
| RAPTRAPT Therapeutics, Inc. | COM | 281,413 | $6.99M | 0.1% | −963,532−77.4% | Reduced | History |
| IMAImageneBio, Inc. | COM | 3,539,358 | $6.97M | 0.1% | +353,192+11.1% | Added | History |
| NSPRInspireMD, Inc. | COM | 2,133,405 | $5.99M | 0.1% | +273,000+14.7% | Added | History |
| XFORX4 Pharmaceuticals, Inc | COM | 7,133,515 | $5.98M | 0.1% | 00.0% | Unchanged | History |
| CGEMCullinan Therapeutics, Inc. | COM | 544,848 | $5.55M | 0.1% | 00.0% | Unchanged | History |
| ORICOric Pharmaceuticals, Inc. | COM | 522,968 | $4.81M | 0.1% | −370,700−41.5% | Reduced | History |
| ILMNIllumina, Inc. | COM | 30,300 | $4.22M | 0.1% | +30,300 | New | History |
| AMAMAmbrx Biopharma, Inc. | COM | 296,000 | $4.22M | 0.1% | +296,000 | New | History |
| NXTCNextCure, Inc. | COM | 2,711,013 | $3.09M | 0.1% | 00.0% | Unchanged | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 58,800 | $2.33M | <0.1% | +58,800 | New | History |
| RCUSArcus Biosciences, Inc. | COM | 117,000 | $2.23M | <0.1% | +117,000 | New | History |
| TXG10x Genomics, Inc. | CL A COM | 39,800 | $2.23M | <0.1% | +39,800 | New | History |
| FATEFate Therapeutics Inc | COM | 528,080 | $1.98M | <0.1% | +528,080 | New | History |
| KZRKezar Life Sciences, Inc. | COM | 1,927,000 | $1.83M | <0.1% | −3,536,000−64.7% | Reduced | History |
| BOLTBolt Biotherapeutics, Inc. | COM | 1,541,000 | $1.73M | <0.1% | 00.0% | Unchanged | History |
| Ys Biopharma Co LtdG9845F109 | ORDINARY SHARES | 3,236,311 | $1.65M | <0.1% | −1,305,111−28.7% | Reduced | – |
| VIGLVigil Neuroscience, Inc. | COM | 448,891 | $1.52M | <0.1% | 00.0% | Unchanged | History |
Options (1)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| PFEPfizer Inc | Stock | – | $14.4M |
Sold out since Q3 2023 (25)
Positions held at the end of Q3 2023 that are gone from this filing.
| Security | Class | Shares in Q3 2023 | Value in Q3 2023 | % of portfolio in Q3 2023 | History |
|---|---|---|---|---|---|
| MRTXMirati Therapeutics, Inc. | COM | 1,959,050 | $85.3M | 2.0% | History |
| BAXBaxter International Inc | Stock | 2,239,900 | $84.5M | 2.0% | History |
| CICigna Group | Stock | 231,500 | $66.2M | 1.5% | History |
| ABBVAbbVie Inc. | Stock | 330,000 | $49.2M | 1.1% | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 253,309 | $37.0M | 0.9% | History |
| HZNPHorizon Therapeutics Public Ltd Co | SHS | 266,400 | $30.8M | 0.7% | History |
| AKROAkero Therapeutics, Inc. | COM | 350,000 | $17.7M | 0.4% | History |
| VTYXVentyx Biosciences, Inc. | COM | 340,384 | $11.8M | 0.3% | History |
| ARQTArcutis Biotherapeutics, Inc. | COM | 1,914,479 | $10.2M | 0.2% | History |
| SGENSeagen Inc. | COM | 42,600 | $9.04M | 0.2% | History |
| GDRXGoodRx Holdings, Inc. | COM CL A | 1,595,000 | $8.98M | 0.2% | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 117,000 | $6.67M | 0.2% | History |
| KVUEKenvue Inc. | Stock | 312,404 | $6.27M | 0.1% | History |
| RLAYRelay Therapeutics, Inc. | COM | 501,966 | $4.22M | 0.1% | History |
| CUTRCutera Inc | COM | 603,100 | $3.63M | 0.1% | History |
| EPIXESSA Pharma Inc. | COM NEW | 842,366 | $2.60M | 0.1% | History |
| KRTXKaruna Therapeutics, Inc. | COM | 14,000 | $2.37M | 0.1% | History |
| TDOCTeladoc Health, Inc. | COM | 110,000 | $2.04M | <0.1% | History |
| BCABBioAtla, Inc. | COM | 1,009,279 | $1.72M | <0.1% | History |
| TARAProtara Therapeutics, Inc. | COM STK | 772,584 | $1.29M | <0.1% | History |
| SYBXSynlogic, Inc. | COM NEW | 401,998 | $1.13M | <0.1% | History |
| DMRADamora Therapeutics, Inc. | COM | 924,788 | $665.4K | <0.1% | History |
| XNCRXencor Inc | COM | 19,142 | $385.7K | <0.1% | History |
| ALTAltimmune, Inc. | COM NEW | 100,000 | $260.0K | <0.1% | History |
| HARPHarpoon Therapeutics, Inc. | COM NEW | 62,121 | $250.3K | <0.1% | History |